A Double-Negative Prostate Cancer Subtype is Vulnerable to SWI/SNF-Targeting Degrader Molecules

To explore the utility of SWI/SNF therapy beyond androgen receptor (AR)-sensitive CRPC, scientists investigated SWI/SNF-targeting agents in AR-negative CRPC.